Notman Donald 4
4 · OCULAR THERAPEUTIX, INC · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Ocular Therapeutuix COO Donald Notman Sells 11,446 Shares
What Happened Donald Notman, Chief Operating Officer of Ocular Therapeutix (OCUL), sold 11,446 shares of common stock on Feb 12, 2026. The weighted average sale price was $9.04 per share, producing gross proceeds of about $103,472. This was a sale (not a purchase) and was executed under an automatic sell-to-cover instruction to satisfy tax withholding on RSU vesting, not as a discretionary trade.
Key Details
- Transaction date: 2026-02-12. Weighted average price: $9.04; price range reported $8.9950–$9.0950 across multiple trades.
- Shares sold/disposed: 11,446; approximate proceeds: $103,472.
- Shares owned after transaction: Not specified in the provided filing excerpt. (See the full Form 4 for post-transaction holdings.)
- Footnotes: F1 — sale executed under a durable automatic sell-to-cover instruction adopted May 13, 2022 to satisfy tax withholding for RSUs that vested Feb 11, 2026; F2 — weighted average price with multiple trade prices; reporting person will provide breakdown on request.
- Filing timeliness: Transaction reported in a Form 4 filed Feb 17, 2026 for a Feb 12, 2026 transaction (filed after the typical two-business-day window), so the filing appears late.
Context This was a routine tax-withholding sell-to-cover following RSU vesting rather than a discretionary sale; such transactions typically reflect tax obligations rather than a change in insider sentiment. The reporting person states the sales were not discretionary and was executed automatically.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-12$9.04/sh−11,446$103,472→ 366,356 total
Footnotes (2)
- [F1]Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 13, 2022, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 11, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.9950 to $9.0950, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.